Clinical Trial Update: Study Evaluating UCART20x22 in B-Cell Non-Hodgkin Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A status update on UCART20x22 in B-cell Non-Hodgkin Lymphoma showing Phase 1/Phase 2 trials currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• UCART20x22

Snippet

Sponsor: Cellectis S.A. | Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL) | Phase 1, Phase 2 | Status: RECRUITING